Although some conflicts exist regarding the relationship between BRAF mutation and clinicopathological characteristics of PTC, BRAF mutation has been reported to be a risk factor for local recurrence and cancer-specific mortality in several studies17–19. This evidence concerns the gene BRAF and cancer.